These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31147244)

  • 1. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized.
    Cristancho P; Lenard E; Lenze EJ; Miller JP; Brown PJ; Roose SP; Montes-Garcia C; Blumberger DM; Mulsant BH; Lavretsky H; Rollman BL; Reynolds CF; Karp JF
    Am J Geriatr Psychiatry; 2019 Oct; 27(10):1138-1152. PubMed ID: 31147244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
    Lenze EJ; Mulsant BH; Roose SP; Lavretsky H; Reynolds CF; Blumberger DM; Brown PJ; Cristancho P; Flint AJ; Gebara MA; Gettinger TR; Lenard E; Miller JP; Nicol GE; Oughli HA; Pham VT; Rollman BL; Yang L; Karp JF
    N Engl J Med; 2023 Mar; 388(12):1067-1079. PubMed ID: 36867173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
    Ji M; Feng J; Liu G
    PLoS One; 2024; 19(4):e0299020. PubMed ID: 38669232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
    Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
    J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
    Lenze EJ; Mulsant BH; Blumberger DM; Karp JF; Newcomer JW; Anderson SJ; Dew MA; Butters MA; Stack JA; Begley AE; Reynolds CF
    Lancet; 2015 Dec; 386(10011):2404-12. PubMed ID: 26423182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
    Mohamed S; Johnson GR; Chen P; Hicks PB; Davis LL; Yoon J; Gleason TC; Vertrees JE; Weingart K; Tal I; Scrymgeour A; Lawrence DD; Planeta B; Thase ME; Huang GD; Zisook S; ; Rao SD; Pilkinton PD; Wilcox JA; Iranmanesh A; Sapra M; Jurjus G; Michalets JP; Aslam M; Beresford T; Anderson KD; Fernando R; Ramaswamy S; Kasckow J; Westermeyer J; Yoon G; D'Souza DC; Larson G; Anderson WG; Klatt M; Fareed A; Thompson SI; Carrera CJ; Williams SS; Juergens TM; Albers LJ; Nasdahl CS; Villarreal G; Winston JL; Nogues CA; Connolly KR; Tapp A; Jones KA; Khatkhate G; Marri S; Suppes T; LaMotte J; Hurley R; Mayeda AR; Niculescu AB; Fischer BA; Loreck DJ; Rosenlicht N; Lieske S; Finkel MS; Little JT
    JAMA; 2017 Jul; 318(2):132-145. PubMed ID: 28697253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
    Gebara MA; DiNapoli EA; Kasckow J; Karp JF; Blumberger DM; Lenze EJ; Mulsant BH; Reynolds CF
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):e330-e335. PubMed ID: 28975710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study).
    Marwood L; Taylor R; Goldsmith K; Romeo R; Holland R; Pickles A; Hutchinson J; Dietch D; Cipriani A; Nair R; Attenburrow MJ; Young AH; Geddes J; McAllister-Williams RH; Cleare AJ
    BMC Psychiatry; 2017 Jun; 17(1):231. PubMed ID: 28651526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.
    Hsu JH; Mulsant BH; Lenze EJ; Sanches M; Karp JF; Reynolds CF; Blumberger DM
    J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General Predictors and Moderators of Depression Remission: A VAST-D Report.
    Zisook S; Johnson GR; Tal I; Hicks P; Chen P; Davis L; Thase M; Zhao Y; Vertrees J; Mohamed S
    Am J Psychiatry; 2019 May; 176(5):348-357. PubMed ID: 30947531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
    Yoon J; Zisook S; Park A; Johnson GR; Scrymgeour A; Mohamed S
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30695291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.
    Morlet E; Costemale-Lacoste JF; Poulet E; McMahon K; Hoertel N; Limosin F;
    J Affect Disord; 2019 Dec; 259():210-217. PubMed ID: 31446382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
    Connolly KR; Thase ME
    Drugs; 2011 Jan; 71(1):43-64. PubMed ID: 21175239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation With Aripiprazole or Bupropion, or a Switch to Nortriptyline, Effective for Treatment-Resistant Depression in Older Adults.
    Ebell MH
    Am Fam Physician; 2023 Sep; 108(3):Online. PubMed ID: 37725473
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports.
    Arandjelovic K; Eyre HA; Lavretsky H
    Am J Geriatr Psychiatry; 2016 Oct; 24(10):913-7. PubMed ID: 27591914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.